CORSA study finds spike-specific blunted immune responses in lymphoma patients after SARS-CoV-2 vaccine - Summary - MDSpire

CORSA study finds spike-specific blunted immune responses in lymphoma patients after SARS-CoV-2 vaccine

  • By

  • Lucia Mazzotti

  • Gerardo Musuraca

  • Fabio Affaticati

  • Esther Bartholomeus

  • Diana Campillo-Davo

  • Carole Faghel

  • Chiara Zingaretti

  • Flavia Foca

  • Claudio Cerchione

  • Valentina Ancarani

  • Patricia Borges de Souza

  • Fabio Nicolini

  • Anna De Lucia

  • Anna Gaimari

  • Oriana Nanni

  • Vittorio Sambri

  • Giovanni Martinelli

  • Francesco Malaspina

  • Pieter Meysman

  • Eva Lion

  • Massimiliano Mazza

  • May 20, 2026

  • 0 min

Share

Objective:

To evaluate humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with hematological malignancies receiving active treatment compared to healthy controls, specifically focusing on the immune dynamics post-vaccination.

Key Findings:
  • Seroconversion rates were significantly lower in lymphoma patients (8% after first dose, 21% after second dose) compared to healthy controls (93% and 100%).
  • 69% of seronegative lymphoma patients exhibited measurable T-cell activity, indicating potential vaccine-induced protection despite low antibody levels.
  • Lymphoma patients demonstrated significantly weaker Spike-specific TCR clonal responses and reduced diversity compared to healthy controls.
Interpretation:

The findings indicate that lymphoma patients have impaired immune responses to SARS-CoV-2 vaccination, which may increase their vulnerability to severe disease.

Limitations:
  • The study focused on a specific cohort of lymphoma patients, limiting generalizability to other hematological malignancies.
  • The sample size may not fully represent the diverse spectrum of hematological malignancies, potentially affecting the robustness of the findings.
Conclusion:

Lymphoma patients exhibit diminished immune responses to SARS-CoV-2 vaccination, highlighting the need for tailored vaccination strategies in this high-risk population to improve their protection against severe disease.

Original Source(s)

CORSA study finds spike-specific blunted immune responses in lymphoma patients after SARS-CoV-2 vaccine

  • by Lucia Mazzotti, Gerardo Musuraca, Fabio Affaticati, Esther Bartholomeus, Diana Campillo-Davo, Carole Faghel, Chiara Zingaretti, Flavia Foca, Claudio Cerchione, Valentina Ancarani, Patricia Borges de Souza, Fabio Nicolini, Anna De Lucia, Anna Gaimari, Oriana Nanni, Vittorio Sambri, Giovanni Martinelli, Francesco Malaspina, Pieter Meysman, Eva Lion, Massimiliano Mazza

  • May 20, 2026

Related Content

HDAC7 controls anti-viral and anti-tumor immunity by CD8+ T cells

High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study

When Adnexal Lymphoma Mimics Retinal Disease